Rein Therapeutics, Inc. (RNTX) Return on equity 2017–2025
Rein Therapeutics, Inc. (RNTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-294.8%FY2025 · since FY2017: -47.3% → -294.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -294.8% | -179.2 pp |
| FY2024 | -115.6% | -99.6 pp |
| FY2023 | -16.0% | +130.7 pp |
| FY2022 | -146.7% | -87.2 pp |
| FY2021 | -59.6% | +165.1 pp |
| FY2020 | -224.7% | -41.7 pp |
| FY2019 | -183.0% | -22.1 pp |
| FY2018 | -161.0% | -113.7 pp |
| FY2017 | -47.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net incomeRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating incomeRNTX Operating marginRNTX Operating cash flowRNTX Free cash flowRNTX Capital expendituresRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Total liabilitiesRNTX Shareholders’ equityRNTX overview →